A phase II, open-label study of the clinical activity, safety, and tolerability of lapatinib in combination with bevacizumab in subjects with advanced or metastatic ErbB2-overexpressing breast cancer.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 10 Jul 2017
At a glance
- Drugs Lapatinib (Primary) ; Bevacizumab
- Indications Advanced breast cancer
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; Novartis
- 06 Jul 2017 Planned End Date changed from 21 Dec 2017 to 31 Dec 2018.
- 25 Jan 2017 Planned End Date changed from 1 Mar 2017 to 21 Dec 2017.
- 19 Apr 2016 Planned End Date changed from 1 Jun 2016 to 1 Mar 2017.